CHEK1 and neoplasm: In summary, we show that pharmacologic tumor PDL1 depletion increases DNA damage, sensitizes a wide variety of human and mouse tumor cells to cytotoxicity from distinct DNA-damaging agents, augments the treatment efficacy to a Chk1 inhibitor in vivo, and activates STING signals, all of which are clinically translatable.